Literature DB >> 11137592

Inhibition of OM pathogens by alpha-hemolytic streptococci from healthy children, children with SOM and children with rAOM.

K Tano1, E Grahn-Håkansson, S E Holm, S Hellström.   

Abstract

The present study was undertaken to elucidate the inhibitory activity of the normal nasopharyngeal flora against the three most common otitis media (OM) pathogens in healthy children, children with secretory otitis media (SOM) and children with recurrent otitis media (rAOM). Isolates of alpha-hemolytic streptococci (AHS) and OM pathogens were recovered from the tubal orifice in each child. The samples were taken from 20 healthy children under general anesthesia, from 19 children with SOM and 20 children with rAOM. The method used to test the bacterial interference in vitro was a modified agar overlay method. The AHS sampled from the tubal orifice of the healthy children were able to inhibit 92% of the S. peumoniae isolates, 74% of the non-typable H. influenzae isolates and 89% of the M. catarrhalis isolates. The corresponding figures for children with SOM and children with rAOM were: 73% of the S. pneumoniae isolates, 58 and 54% of the non-typable H. influenzae isolates and 86 and 89% of the M. catarrhalis isolates. The AHS from children with SOM and children with rAOM were significantly less capable of inhibiting the S. peumoniae and the H. influenzae isolates (P<0.001). There was no significant difference between the three groups of children regarding inhibitory activity against M. catarrhalis. The results suggest that the inhibitory activity of the normal bacterial flora at the tubal orifice against pneumococci and H. influenzae may be reduced in children with SOM and rAOM.

Entities:  

Mesh:

Year:  2000        PMID: 11137592     DOI: 10.1016/s0165-5876(00)00428-6

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  8 in total

1.  Detection and serotyping of Streptococcus pneumoniae from nasopharyngeal samples by PCR-based multiplex assay.

Authors:  Jaime Moreno; Elkin Hernández; Olga Sanabria; Elizabeth Castañeda
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.

Authors:  Darlington M Mwenya; Bambos M Charalambous; Patrick P J Phillips; James C L Mwansa; Sarah L Batt; Andrew J Nunn; Sarah Walker; Diana M Gibb; Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

3.  The Use of Probiotics in Head and Neck Infections.

Authors:  Kristian Roos; Stig Holm
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

4.  Upper respiratory tract microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children.

Authors:  Melinda M Pettigrew; Alison S Laufer; Janneane F Gent; Yong Kong; Kristopher P Fennie; Joshua P Metlay
Journal:  Appl Environ Microbiol       Date:  2012-06-29       Impact factor: 4.792

5.  Impact of respiratory viral infections on α-hemolytic streptococci and otopathogens in the nasopharynx of young children.

Authors:  Victoria Friedel; Arthur Chang; Jennifer Wills; Roberto Vargas; Qingfu Xu; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

6.  Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli--an in vitro study.

Authors:  Pamela Hasslöf; Maria Hedberg; Svante Twetman; Christina Stecksén-Blicks
Journal:  BMC Oral Health       Date:  2010-07-02       Impact factor: 2.757

7.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

Review 8.  Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

Authors:  Stephen K Obaro; Shabir A Madhi
Journal:  Lancet Infect Dis       Date:  2006-03       Impact factor: 25.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.